Inoviq Accelerates Exosome Diagnostics and Therapies After Capital Raise and Positive TNBC Data

An announcement from Inoviq Ltd ( (AU:IIQ) ) is now available.

In its December quarterly update, Inoviq reported continued commercial uptake of its EXO-NET exosome capture technology, with 76 customers by year-end and growing demand from pharma, biotech and clinical users despite broader funding uncertainty in the life sciences tools sector. The company advanced its EXO-OC exosome-based ovarian cancer screening test toward larger clinical studies after earlier data showed 100% sensitivity for early-stage disease and more than 99.6% specificity, and it is targeting Laboratory Developed Test readiness by end-2026 while exploring US laboratory partnerships. Inoviq also announced strong in vivo proof-of-concept results for its EGFR-targeted CAR-NK exosome therapy in a triple-negative breast cancer mouse model, demonstrating superior tumour inhibition, favourable safety and precise tumour targeting, and is accelerating this program into preclinical and manufacturing development with a view to first-in-human studies in 2028. Complementing these programs, the company is further developing its neuCA15-3 blood test for breast cancer monitoring into a high-throughput assay ahead of additional clinical validation and potential partnering, while shoring up its balance sheet with a A$10.2 million capital raise and ending the quarter with $13.8 million in cash, alongside leadership changes including a new chairman and chief scientific officer to support its next growth phase.

The most recent analyst rating on (AU:IIQ) stock is a Hold with a A$0.37 price target. To see the full list of analyst forecasts on Inoviq Ltd stock, see the AU:IIQ Stock Forecast page.

More about Inoviq Ltd

Inoviq Limited is an Australian life sciences company focused on exosome-based diagnostics and therapeutics, as well as cancer monitoring assays. Its key products include the EXO-NET exosome capture technology, which is sold globally through Promega to academic, government, pharma/biotech and clinical customers, and pipeline tests such as the EXO-OC ovarian cancer screening blood test and the neuCA15-3 breast cancer monitoring assay. The company targets oncology and other disease areas where early detection and precise monitoring can improve treatment outcomes, and it is developing next-generation exosome-based cell-free therapies for hard-to-treat solid tumours.

Average Trading Volume: 124,614

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$53.49M

Learn more about IIQ stock on TipRanks’ Stock Analysis page.